CAMP4 Therapeutics (NASDAQ:CAMP) Posts Quarterly Earnings Results, Misses Estimates By $0.17 EPS

CAMP4 Therapeutics (NASDAQ:CAMP) posted its quarterly earnings data on Thursday. The Wireless communications provider reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.17), FiscalAI reports. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.90 million during the quarter.

CAMP4 Therapeutics Trading Up 3.5%

Shares of NASDAQ:CAMP traded up $0.13 during trading on Friday, reaching $3.85. 29,808 shares of the stock were exchanged, compared to its average volume of 201,495. CAMP4 Therapeutics has a 12 month low of $2.90 and a 12 month high of $7.75. The stock has a 50-day moving average price of $3.84 and a 200-day moving average price of $4.20. The firm has a market cap of $241.60 million, a PE ratio of -1.66 and a beta of 0.28.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Chardan Capital cut their price objective on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Oppenheimer assumed coverage on shares of CAMP4 Therapeutics in a report on Monday, October 5th. They set an “outperform” rating and a $15.00 target price on the stock. Raymond James Financial assumed coverage on shares of CAMP4 Therapeutics in a report on Friday, October 23rd. They issued a “strong-buy” rating and a $10.00 target price on the stock. Finally, Wall Street Zen lowered CAMP4 Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.44.

Insider Buying and Selling

In other news, CFO Kelly Gold purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average cost of $3.96 per share, with a total value of $39,600.00. Following the acquisition, the chief financial officer owned 10,000 shares in the company, valued at approximately $39,600. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Andrew Schwab sold 400,000 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the sale, the director owned 2,033,270 shares of the company’s stock, valued at $8,214,410.80. This trade represents a 16.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 593,613 shares of company stock worth $2,504,037. 21.69% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE bought a new stake in CAMP4 Therapeutics in the 2nd quarter valued at about $78,000. Deutsche Bank AG bought a new position in shares of CAMP4 Therapeutics during the second quarter worth approximately $138,000. Bank of New York Mellon Corp acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at approximately $365,000. SummitTX Capital L.P. acquired a new stake in shares of CAMP4 Therapeutics in the first quarter valued at approximately $1,497,000. Finally, BlackRock Inc. acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at approximately $7,185,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.